A Product of Pooled Human Plasma — Given to Every Rh-Negative Woman
Approximately 15% of women are Rh-negative. In a pregnancy where the father is Rh-positive and fetal blood mixes with maternal blood, the mother's immune system can become sensitized to the Rh-positive protein — potentially creating antibodies that could attack red blood cells in a future Rh-positive pregnancy. This is a real condition: Rh hemolytic disease of the fetus and newborn (HDFN). Before RhoGAM, it caused significant fetal mortality.
RhoGAM is a blood-derived product — manufactured from pooled plasma from multiple Rh-positive donors — that delivers pre-formed anti-D antibodies. Given within 72 hours of a sensitizing event (blood mixing), it prevents maternal sensitization. This is its mechanism. This is what it does.
The clinical problem is not RhoGAM itself. The problem is how it has been deployed: as a universal routine injection at 28 weeks of gestation to every Rh-negative woman — without determining whether there is a sensitizing event to prevent, without testing whether the father is Rh-negative (which would make the injection meaningless), and without a full accounting of what is in the vial beyond what the manufacturer chooses to list.
The Mercury History — What the FDA Documented
This is not a conspiracy theory. It is on the FDA's own website, under "Mercury in Plasma-Derived Products," last updated March 23, 2018.
(standard dose, pre-2001)
Ortho Clinical Diagnostics
(0.01% thimerosal — 3× higher
than RhoGAM)
Bayer Corporation, pre-1996
RhoGAM. 2-year dating period means
all thimerosal RhoGAM expired
by ~2003.
The 35 mcg figure for BayRho is rarely cited. It was a higher-mercury product that remained in circulation until 1996 — a full five years longer than is commonly discussed. Any Rh-negative woman who received BayRho between 1971 and 1996 received more than three times the mercury dose that RhoGAM delivered.
An Rh-negative woman pregnant between the late 1980s and 2001 received this injection at 28 weeks gestation — delivering ethylmercury directly into her bloodstream during active fetal neurodevelopment. She received it again within 72 hours of delivery. Many also received it after miscarriages, amniocentesis, and other sensitizing events.
The children born to those women are today between their mid-20s and early 40s. They are the cohort that corresponds to the sharpest rise in autism diagnoses.
What "Thimerosal-Free" Actually Means
The FDA defines "thimerosal-free" as containing ≤0.3 mcg thimerosal per dose — not zero. It is a reduced-mercury threshold, not a mercury-free standard. This definitional distinction is not disclosed to patients.
What independent testing found — HAPI, 2004
Health Advocacy in the Public Interest (HAPI) conducted independent laboratory testing of vaccine and biological vials labeled "mercury-free" or "thimerosal-free." Their findings: every vial tested contained measurable mercury. The reason: mercury binds to the antigenic proteins in the product. Once bound, it cannot be fully filtered out. The manufacturing process uses thimerosal; the filtration step removes what it can; the remainder stays in the vial bound to the proteins that are the active ingredient.
Every vial tested also contained aluminum — not listed as an ingredient because it is not intentionally added, but present as a manufacturing process residual. The package insert documents what is added. It does not document what the manufacturing process leaves behind.
This is the distinction between a listed ingredient and a contaminant. The label is not a complete chemical inventory of the vial's contents. It is a list of intentional additions.
The documentary Trace Amounts (2014) examines this directly — the principle that trace quantities of neurotoxins, particularly in combination, can be catastrophic during fetal neurodevelopment. The fetal brain is not an adult brain. It does not have a mature blood-brain barrier. Mercury does not have to be present in large amounts to disrupt the methylation pathways, the neural crest cell migration, and the synaptic architecture that are being built during that window.
The University of Washington primate study (Burbacher et al., 2005, Environmental Health Perspectives) established the mechanism clearly: ethylmercury from thimerosal clears from blood faster than methylmercury, which was used to argue it was safer. What Burbacher found was that the mercury didn't disappear — it redistributed to brain tissue as inorganic mercury at twice the rate of methylmercury. Inorganic mercury in neural tissue has a half-life measured in years. The blood cleared quickly. The brain did not.
The Research on Rh-Negative Mothers and Autism
In 2007, Mark Geier MD and David Geier published a prospective study in the Journal of Maternal-Fetal and Neonatal Medicine. They looked at 53 consecutive non-Jewish Caucasian patients with confirmed ASD diagnosis and compared them against 926 controls. Their finding: 28.3% of ASD children had Rh-negative mothers, versus 14.4% of controls — approximately double the expected rate.
The following year (2008), they published a multi-center study across two independent clinical sites with 298 children with neurodevelopmental disorders and over 1,000 controls. Both sites found the same pattern: maternal Rh-negativity at approximately 25–28% in ASD cohorts versus 12–14% in controls.
The most important finding from the 2008 study: children with neurodevelopmental disorders born after 2001 — after thimerosal was removed from RhoGAM — showed maternal Rh-negativity rates of 13.6%, statistically indistinguishable from controls. The elevated rate existed in the pre-2001 birth cohort. It normalized in the post-2001 cohort.
A temporal pattern is not the same as proof of causation. But it is the kind of data pattern that would, in any other context, trigger a formal investigation. The temporal pattern here — elevated maternal Rh-negativity rates in ASD cohorts from the thimerosal era, normalization in the post-thimerosal era — is coherent with the mercury hypothesis and has not been refuted by any study that examined the same birth cohort comparison.
The refuting study (Croen et al., 2008, Kaiser Permanente Northern California) found no association — but examined a different question: current anti-D exposure status, not birth-year thimerosal cohort comparison. These studies are measuring different things.
Note on the Geier researchers: Mark and David Geier subsequently developed and marketed a Lupron protocol for autism treatment — a protocol that caused documented harm to children and resulted in Mark Geier's medical license being revoked in all states between 2011 and 2013. Their clinical conduct is not a defense of those children. But the observational epidemiological data from 2007–2008 — the temporal pattern, the independent two-site replication — does not become false because the researchers later caused harm in a different context. Data stands or falls on methodology, not on subsequent biography.
The Pooled Plasma Problem
RhoGAM is manufactured from pooled human plasma — the antibodies of multiple donors combined into each vial. This is how all immunoglobulin products work. It is also an inherent risk vector that is almost never discussed in the consent conversation.
It is virtually impossible to screen and test out every potential pathogen from pooled plasma. Manufacturing processes reduce viral load through steps like solvent-detergent treatment and nanofiltration, but these methods have known limitations — they do not neutralize all pathogens equally, and novel or non-enveloped viruses can slip through.
A pregnant woman at 28 weeks is receiving a blood-derived product pooled from multiple donors, injected directly into her bloodstream, with the unknown viral landscape of those donors, at a moment when fetal immune development is actively underway. This risk is real, it is documented in the prescribing information, and it is essentially never mentioned in the prenatal examination room.
The standard they apply in the emergency room — and abandon at the prenatal visit.
If you arrive at an emergency room and need a blood transfusion, the first thing they do is type and cross-match your blood. They identify your ABO blood group and Rh status, and they select donor blood matched specifically to you. Giving the wrong blood type causes hemolytic reaction. It can kill you. This is why matching is non-negotiable in transfusion medicine.
RhoGAM is pooled from donors of all blood types — O, A, B, AB — combined into a single product. An Rh-negative woman receiving it is being injected with plasma-derived antibodies from people who may be blood type O, AB, A, or B. There is no individual matching. There is no cross-match. The standard of care that is considered mandatory for a direct blood transfusion simply does not apply to this product — because it has been classified as an immunoglobulin rather than a transfusion, and that classification places it outside the matching protocols.
The same woman who would never be given unmatched blood in an emergency room receives a pooled multi-donor blood product at her 28-week prenatal appointment without a second thought — from her provider or from her. That is the informed consent gap in a single comparison.
It only makes sense if you don't think about it.
A Paradox Built Into the Shot
The mechanism of RhoGAM is that it introduces Rh antibodies into the mother's bloodstream to prevent sensitization. Those antibodies remain in circulation for approximately 12 weeks after injection.
If any blood mixing occurs during that 12-week window — a fall, a car accident, any trauma to the abdomen — those Rh antibodies can cross the placenta and enter the fetal bloodstream. The result: the very Rh disease the shot was designed to prevent, delivered to the fetus by the protective intervention itself.
This is not a theoretical concern. It is documented in the pharmacology of the product. It is one reason the original clinical protocol — administer RhoGAM only after a confirmed sensitizing event, not prophylactically — was the standard of care before the routine 28-week injection became standard practice.
What the Body May Be Doing on Its Own
The standard framing assumes that without RhoGAM, an Rh-negative mother carrying an Rh-positive baby will sensitize — develop anti-D antibodies — and that her next Rh-positive pregnancy will be at risk for hemolytic disease of the newborn (HDN). That risk is real. It is also not universal, and it is not as automatic as the routine injection protocol implies.
Without prophylaxis, the sensitization rate following a first Rh-positive pregnancy is approximately 16%. That means roughly 84% of Rh-negative women who carry an Rh-positive baby to term do not develop anti-D antibodies — without any intervention. Their immune systems do not mount the response the drug is designed to prevent. This documented reality is almost never part of the informed consent conversation, because the conversation is structured around universal prophylaxis, not individual risk assessment.
There is emerging research — not yet mainstream — suggesting that the maternal immune system may actively adapt to protect an Rh-positive fetus rather than attack it.
Fetal microchimerism — the passage of fetal cells into the maternal circulation during pregnancy — is now well established. These fetal cells can persist in maternal tissue for decades. Some researchers have proposed that this bidirectional cellular exchange includes immune signaling that allows the maternal system to develop tolerance to fetal antigens, including Rh-positive blood group proteins. If this tolerance mechanism operates in a significant proportion of Rh-negative women, the routine prophylactic injection at 28 weeks — given before any confirmed mixing event and before any evidence of sensitization — preempts a process the body may have managed without intervention.
This research is preliminary. What is not preliminary is the 84% non-sensitization rate. That number is in the clinical literature. It is the number that informed consent requires.
The question that genuine informed consent would require answering: given that most Rh-negative women do not sensitize in their first Rh-positive pregnancy — and given that sensitization can be monitored throughout pregnancy with a simple antibody titer — why is a pooled human blood plasma product injected at 28 weeks into every Rh-negative woman, before any evidence that sensitization is occurring?
The Risk Profile of a Blood Plasma Product — What Informed Consent Requires
RhoGAM is not a vaccine. It is an immunoglobulin derived from pooled human plasma. Every pooled blood product carries a risk profile that is distinct from, and broader than, a single-donor transfusion. This profile is disclosed in the prescribing information. It is almost never disclosed to the pregnant woman receiving the injection.
Celiac disease and autoimmune GI conditions
Pooled immunoglobulin products introduce foreign antibodies and immune complexes into the recipient's bloodstream. There is a documented association between early immunoglobulin exposure and subsequent development of autoimmune conditions affecting the gut. Celiac disease — an autoimmune response to gluten driven by immune system dysregulation — has increased dramatically in prevalence over the same decades that routine immunoglobulin prophylaxis expanded. The causal picture is complex, but the temporal correlation and mechanistic plausibility are both present.
Autism spectrum disorder
The Geier research (2007, 2008) documented a statistically significant temporal pattern between RhoGAM administration rates and autism diagnosis rates across US birth cohorts — with the thimerosal-preserved formulation showing the strongest signal. Subsequent research has examined the maternal immune activation pathway: foreign immune proteins crossing the placenta, activating fetal immune responses during critical windows of neural development. This remains an area of active and contested research. It is not mentioned in the consultation room.
Autoimmune disease
Any introduction of pooled foreign immunoglobulins carries theoretical risk of immune complex formation and autoimmune priming. The prescribing information for RhoGAM explicitly lists hemolytic reactions, pulmonary events, and renal failure as documented adverse events with IV formulations. IM administration (the standard prenatal route) carries a lower acute risk profile — but the long-term immune consequences of early-life immunoglobulin exposure in the fetus and newborn are not well characterized in the independent literature.
Viral transmission and cancer risk
Pooled plasma manufacturing cannot screen out every pathogen. Solvent-detergent treatment and nanofiltration — the standard reduction steps — do not neutralize all non-enveloped viruses or prions. Historically, pooled blood products caused large-scale transmission of HIV and hepatitis C before adequate testing was available. Current manufacturing is significantly safer. It is not categorically safe. The prescribing information states: "Because Rh₀(D) Immune Globulin is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent." Viral integration events and long-term oncogenic risk from pooled immunoglobulin products have not been studied in the prenatal cohort at the depth the exposure warrants.
The informed consent that does not happen.
An Rh-negative woman at 28 weeks is typically told: "You need this shot because your baby might be Rh-positive, and without it your next pregnancy could be at risk." She is not told: that 84% of Rh-negative women do not sensitize in a first pregnancy without intervention; that her antibody titers can be monitored throughout pregnancy to determine whether sensitization is actually occurring; that the product is derived from pooled human plasma with the pathogen risks that entails; that the prescribing information lists celiac, autoimmune conditions, viral transmission, and cancer risk as documented or theoretical risks; that there is research — not yet definitive, but not dismissible — connecting thimerosal-preserved formulations to autism rates in exposed birth cohorts; or that selective, event-based administration (rather than universal prophylaxis) was the original standard of care. That conversation would take ten minutes. It almost never happens.
When RhoGAM Is — and Is Not — Medically Indicated
The questions below are the ones that should happen before any Rh-negative woman agrees to this injection. They almost never do.
Question 1: Is the father of this baby Rh-negative?
If both parents are Rh-negative, the baby cannot be Rh-positive. There is no Rh-positive protein in the fetal blood. There is no mechanism by which sensitization can occur. The injection has no function, carries all of its risks, and no benefit whatsoever.
If both parents are Rh-negative: some clinicians consider the injection unnecessary in this scenario. This is a clinical question worth raising directly with your provider — ask about both parents' Rh status and what the specific indication is for your situation. Accepting it in this scenario introduces risk with zero offsetting benefit — and introduces Rh antibodies into the maternal bloodstream that could, in the event of any trauma, reach a baby that has no Rh-positive blood to cause disease.
Question 2: Has a sensitizing event occurred?
The medical logic of RhoGAM is event-response: it works when given within 72 hours of a confirmed sensitizing event — blood mixing between maternal and fetal circulation. Sensitizing events include: miscarriage, ectopic pregnancy, amniocentesis, chorionic villus sampling (CVS), significant trauma to the abdomen, external cephalic version (ECV), and delivery.
A routine 28-week injection is not a response to a sensitizing event. It is a prophylactic given without confirming that any event has occurred, will occur, or is likely to occur. The shot at 28 weeks provides no protection to the current baby — sensitization from any blood mixing during gestation affects only future pregnancies. The 28-week shot's only function is to reduce sensitization risk from a hypothetical event that may or may not happen in the remaining 12 weeks of pregnancy.
Question 3: After birth — is the baby Rh-positive?
Cord blood can be typed immediately after delivery. if the baby is confirmed Rh-negative, the post-delivery RhoGAM injection may not serve its intended function — a clinical question worth discussing with your provider after delivery. If the baby is Rh-positive, the next question is whether any blood mixing occurred — which is most likely with interventionist deliveries (induction, epidural, C-section, forceps, vacuum) and far less likely with a natural birth where the placenta was permitted to detach physiologically.
The standard of care in the original protocol: wait for cord blood type confirmation, then administer RhoGAM only if the baby is Rh-positive and clinical judgment indicates blood mixing was likely. This is still defensible medicine. It is simply not what happens in most hospitals today.
Summary — The Decision Framework
| Scenario | RhoGAM Indicated? |
|---|---|
| Both parents Rh-negative — any point in pregnancy or post-delivery | No. Never. |
| Rh-negative mother, Rh-positive father, no sensitizing event — 28 weeks routine | Questionable. No confirmed sensitizing event. Protects only future pregnancies from hypothetical mixing in the last trimester. |
| Rh-negative mother + confirmed sensitizing event (miscarriage, CVS, amnio, significant trauma, ECV) | Potentially indicated. Within 72 hours of the event. |
| Post-delivery, baby confirmed Rh-positive, interventionist birth (induction, epidural, C-section) | Most defensible indication. Protect future pregnancies from confirmed exposure context. |
| Post-delivery, baby confirmed Rh-negative | No. No Rh-positive blood exposure occurred. |
| Post-delivery, natural birth, physiological placental detachment, baby Rh-positive | Lower indication. Blood mixing in natural delivery with intact placenta is less likely. Individual clinical judgment applies. |
Questions to bring to your provider
- ●What is the father's Rh status? Has he been typed?
- ●Has a sensitizing event occurred that warrants this injection now?
- ●Can we wait until after delivery to type the cord blood before deciding on post-delivery RhoGAM?
- ●What are the current independent laboratory findings on trace mercury and aluminum in thimerosal-free formulations?
- ●What viral screening was performed on the donor pool for this lot?
- ●If I decline the routine 28-week shot and have a natural birth with no intervention, what is my actual statistical risk of sensitization?
- ●Given that 84% of Rh-negative women do not sensitize in a first Rh-positive pregnancy without intervention, can we monitor my antibody titers throughout this pregnancy and make the decision based on my individual response rather than universal protocol?
- ●This product is derived from pooled human plasma. What is the documented risk profile for cancer, autoimmune disease, celiac disease, and autism in children exposed in utero — and has that risk been weighed against my individual sensitization risk before recommending this?
Research, Sources & Further Reading
Official Sources
FDA — Mercury in Plasma-Derived Products
Documents historical thimerosal content: RhoGAM 10.5 mcg ethylmercury per dose (pre-2001); BayRho 35 mcg per dose (pre-1996); WinRho never contained thimerosal. Last updated March 23, 2018.
fda.gov/vaccines-blood-biologics/safety-availability-biologics/mercury-plasma-derived-products
FDA DailyMed — RhoGAM Ultra-Filtered PLUS (Current Prescribing Information)
Current formulation: sodium chloride, polysorbate 80, glycine. No thimerosal, no preservatives, no aluminum listed. Note: listed ingredients are intentionally added ingredients — not a complete trace-element inventory of the final product.
Published Research
Geier DA, Geier MR. — A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders
Journal of Maternal-Fetal and Neonatal Medicine, 2007; 20(5):385–390. PMID: 17674242 · 53 ASD cases vs. 926 controls · Maternal Rh-negativity 28.3% vs. 14.4% (P < .01)
Geier DA, Mumper E, Gladden M et al. — Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment
Neuroendocrinology Letters, 2008; 29(2):272–280. PMID: 18404135 · Two independent clinical sites · 25–28% Rh-negative in ASD cohorts vs. 12–14% controls · Post-2001 birth cohort: 13.6% Rh-negative — normalized to control level
Burbacher TM et al. — Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal
Environmental Health Perspectives, 2005; 113(8):1015–1021. PMID: 16079072 · Brain inorganic mercury 2× higher from thimerosal than methylmercury · Blood clearance fast; neural clearance measured in years
Deth RC, Waly M et al. — Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal
Molecular Psychiatry, 2004; 9(4):358–370. PMID: 14745455 · Thimerosal inhibits methionine synthase at 1 nM — disrupts neuronal methylation at extraordinarily low concentrations
Bernard S, Enayati A, Redwood L et al. — Autism: a novel form of mercury poisoning
Medical Hypotheses, 2001; 56(4):462–471. PMID: 11339848 · Review of 100+ mercury toxicology studies; clinical overlap argument; RhoGAM as prenatal source
Croen LA, Matevia M, Yoshida CK, Grether JK. — Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and risk of autism spectrum disorders
American Journal of Obstetrics and Gynecology, 2008; 199(3):234.e1–6. PMID: 18554566 · Kaiser Permanente study · No significant association found · Note: did not compare pre- vs. post-thimerosal birth cohorts
Independent Testing
HAPI — Health Advocacy in the Public Interest, 2004
Independent laboratory testing of "thimerosal-free" biological vials. Finding: all vials tested contained measurable mercury (mercury binds to antigenic proteins and cannot be fully filtered); all vials also contained aluminum (manufacturing process residual, not listed as an ingredient). Published limitation: not a peer-reviewed study; methodology not publicly available for independent verification.
Documentary
Trace Amounts (2014)
Documentary examining thimerosal, the Simpsonwood closed-door CDC meeting (2000), and the principle that trace amounts of neurotoxins — particularly in combination and in the developing fetal brain — can be catastrophic. Available on multiple platforms.
Related Pages
Related: Pap Smear & Gynecological Procedures
Ethylene oxide sterilization, LEEP preterm birth risk, colposcopy tools — the same informed consent gaps in gynecological care
Go deeper →Related: Vaccines in Pregnancy
Tdap aluminum content (0.3 mg per dose), flu shot, the full injection schedule for pregnant women
Go deeper →